Solara Active Pharma Sciences
Solara Active Pharma Sciences Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Solara Active Pharma Sciences Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Valuation
Profitability
Growth
Financial Health
Solara Active Pharma Sciences Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Solara Active Pharma Sciences Ltd, switchable between annual and quarterly views, consolidated or standalone.
Solara Active Pharma Sciences Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹2,957.39 Cr and reported EPS of ₹-1.68.
| Period | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,289 | 1,284 | 1,369 |
| Other Income | 12 | 28 | 29 | 20 | 23 | 5 | 8 | 6 |
| Total Income | 1,399 | 1,349 | 1,646 | 1,288 | 1,466 | 1,294 | 1,292 | 1,375 |
| Cost of Goods Sold (COGS) | 705 | 599 | 724 | 654 | 789 | 805 | 626 | 685 |
| Gross Profit | 682 | 723 | 892 | 614 | 655 | 484 | 657 | 684 |
| +Operating Expenses | 461 | 463 | 507 | 534 | 521 | 579 | 451 | 498 |
| EBITDA | 221 | 259 | 386 | 80 | 134 | -95 | 206 | 187 |
| +Non-Operating Expenses | 166 | 172 | 193 | 184 | 201 | 18 | 214 | 189 |
| Profit Before Tax (PBT) | 68 | 115 | 222 | -91 | -45 | -488 | 1 | -7 |
| +Tax Expense | 1 | 0 | 0 | -33 | -23 | 79 | — | — |
| Profit After Tax (PAT) | 59 | 115 | 221 | -58 | -22 | -567 | 1 | -7 |
| Earnings Per Share (EPS) | 17.29 | 32.01 | 46.22 | -12.12 | -4.62 | -118.22 | 0.11 | -1.54 |
| Diluted Shares Outstanding (Nos.) | 3 | 4 | 5 | 5 | 5 | 5 | 5 | 5 |
| +Additional Disclosures | 2,026 | 1,829 | 2,146 | 2,032 | 2,298 | 2,398 | 1,919 | 2,064 |
| Sales Growth % | — | -4.68 | 22.33 | -21.56 | 13.83 | -10.73 | -0.40 | 6.64 |
| YoY Sales Growth % | — | -4.68 | 22.33 | -21.56 | 13.83 | -10.73 | -0.40 | 6.64 |
| Material Cost % | 53 | 46 | 42 | 68 | 54 | 59 | 45 | 49 |
| Employee Cost % | 13 | 15 | 14 | 19 | 16 | 19 | 16 | 16 |
| Other Cost % | 20 | 20 | 17 | 24 | 20 | 26 | 19 | 20 |
| OPM % | 16 | 20 | 24 | 6 | 9 | -7 | 16 | 14 |
| Tax % | 1 | 0 | 0 | 36 | 50 | -16 | — | — |
| Profit Growth % | — | 92.73 | 93.29 | -126.33 | 61.85 | -2,449.28 | 100.10 | -1,472.22 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 | -0.00 | 0.00 | 0.00 |
| Additional Fields | 138 | 165 | 277 | -32 | 23 | -199 | 107 | 87 |
Solara Active Pharma Sciences segment analysis: revenue and profit mix.
Disclosed business segments at Solara Active Pharma Sciences with their share of revenue and profit, switchable between consolidated and standalone reporting.
Solara Active Pharma Sciences discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Solara Active Pharma Sciences Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Solara Active Pharma Sciences Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Solara Active Pharma Sciences Ltd's investment case rests on 9 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
Quarterly profit after tax surged 178.00% to 10.5 Cr.
Promoter holding increased to 42.01% from 30.49%, indicating confidence.
Healthy operating profit margin of 17.90% reflects efficient core operations.
Manageable debt-to-equity ratio of 0.73 suggests financial stability.
Diverse API portfolio and global reach across multiple therapeutic areas.
What can break it.
Extremely low profitability. ROE 0.54% and ROCE 6.01% indicate inefficient capital use.
High P/E ratio of 112.97 suggests the stock may be overvalued.
Quarterly sales declined by -12.20%, signaling weakening demand.
Significant negative long-term growth. EPS CAGR -68.33% over 5 years.
Negative 5-year profitability trends. ROA -3.68% and Net Profit Margin -7.28%.
What would change my mind.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 55.18. Balance sheet risk re-prices growth multiples fast.
Solara Active Pharma Sciences Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Solara Active Pharma Sciences Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Solara Active Pharma Sciences Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Solara Active Pharma Sciences Ltd — derived from the live tape, not yesterday's close.
Solara Active Pharma Sciences Ltd last traded at ₹608.55 with an intraday range of ₹581.05–₹619.9 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹608.55| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 702.98 | +94.43 | +15.52% |
| R3 | 664.13 | +55.58 | +9.13% |
| R2 | 642.02 | +33.47 | +5.50% |
| R1 | 625.28 | +16.73 | +2.75% |
| PIVOT | 603.17 | -5.38 | -0.88% |
| CURRENT | 608.55 | — | — |
| S1 | 508.73 | -99.82 | -16.40% |
| S2 | 547.58 | -60.97 | -10.02% |
| S3 | 564.32 | -44.23 | -7.27% |
| S4 | 586.43 | -22.12 | -3.63% |
SOLARA is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: 581.05 ~ 605.9
Trading Inside opening range
Solara Active Pharma Sciences Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Solara Active Pharma Sciences Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Solara Active Pharma Sciences Ltd stood at 25.7% of traded volume, against a 20-day average of 34.5%.
Solara Active Pharma Sciences announcements: results, concalls, ratings, M&A.
Filings Solara Active Pharma Sciences sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Solara Active Pharma Sciences files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 129 documents below.
Disclosure under SEBI Takeover Regulations
Pronomz Ventures LLP has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India…
Analysts/Institutional Investor Meet/Con. Call Updates
Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings conference call pertaining to financial results of the…
General Updates
Solara Active Pharma Sciences Limited has informed the exchange regarding the approval and adoption of Board Evaluation policy and amendment to…
Statement of deviation(s) or variation(s) under Reg. 32
Solara Active Pharma Sciences Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
ESOP/ESOS/ESPS
Solara Active Pharma Sciences Limited has informed the exchange regarding allotment of 2,200 Equity Shares pursuant to exercise of ESOP Options.
Investor decks & rating reports.
Solara Active Pharma Sciences insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Solara Active Pharma Sciences as reported to SEBI — buying and selling signals from the people who know the business best.
Solara Active Pharma Sciences insider activity below tracks 7 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Sandeep Shashikantha Rao | Insider | 04 Jun 2025 | buy | +1.0 K | ₹4.74 L | ₹473.99 |
| Kausalya Santhanam | Insider | 11 Mar 2025 | buy | +1.0 K | ₹5 L | ₹500.06 |
| Pronomz Ventures LLP | Insider | 28 Feb 2025 | buy | +13.6 K | ₹62.76 L | ₹461.50 |
| Pronomz Ventures LLP | Insider | 24 Feb 2025 | buy | +1.52 L | ₹7.2 Cr | ₹473.48 |
| Pronomz Ventures LLP | Insider | 24 Feb 2025 | buy | +2.16 L | ₹10.26 Cr | ₹474.31 |
| Pronomz Ventures LLP | Insider | 11 Feb 2025 | buy | +34.0 K | ₹1.78 Cr | ₹524.82 |
| Pronomz Ventures LLP | Insider | 03 Feb 2025 | buy | +78.0 K | ₹4.03 Cr | ₹516.68 |
Solara Active Pharma Sciences dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Solara Active Pharma Sciences has declared, sequenced by announce and record date.
Solara Active Pharma Sciences corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Solara Active Pharma Sciences Ltd: business, sector, key facts.
What Solara Active Pharma Sciences Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Solara Active Pharma Sciences Ltd operates in the Healthcare, listed as NSE: SOLARA, BSE: 541540.
Solara Active Pharma Sciences Limited is a global pharmaceutical company specializing in the manufacture, production, formulation, and distribution of active pharmaceutical ingredients (APIs). Their operations span a wide geographical area, including India, the Asia-Pacific region, Europe, North America, and South America, facilitating international trade and sales.
The company's API portfolio is extensive and covers a broad range of therapeutic areas. They produce APIs for various conditions, including amyotrophic lateral sclerosis, cardiovascular diseases, neurological disorders (like Parkinson's disease), infections (antibiotics, antifungals), and respiratory ailments (like asthma). Other therapeutic categories include anti-inflammatory, anti-cancer, anti-hypertensive, and anti-psychotic medications, amongst many others. The sheer breadth of their API offerings highlights their diverse capabilities and expertise within the pharmaceutical manufacturing sector.
Beyond API production, Solara Active Pharma Sciences also provides comprehensive contract research and manufacturing services (CRAMS). This service offering includes contract development and manufacturing of APIs, along with crucial support services such as analytical testing, impurity synthesis, and regulatory assistance. These added services enhance their value proposition to pharmaceutical clients seeking outsourced manufacturing and development solutions.
In essence, Solara Active Pharma Sciences Limited functions as a fully integrated pharmaceutical company. They not only manufacture and distribute a vast array of APIs for various therapeutic applications but also offer comprehensive CRAMS capabilities, enabling them to serve a diverse client base across the global pharmaceutical industry. Their international reach and broad portfolio position them as a significant player in the API market.
Questions investors ask about Solara Active Pharma Sciences Ltd (SOLARA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Solara Active Pharma Sciences Ltd (SOLARA)?
The current share price of Solara Active Pharma Sciences Ltd (SOLARA) is ₹608.55. Today, the stock has gained by ₹27.85 (4.80%), trading in a range of ₹581.05 to ₹619.9. The stock opened at ₹581.05 with a trading volume of 6,64,223 shares.
02Is Solara Active Pharma Sciences Ltd stock a good investment for long-term?
Solara Active Pharma Sciences Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,957.39 crores, P/E ratio of 0.00, ROE of -0.63%, and ROCE of 6.01%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Solara Active Pharma Sciences Ltd stock?
The 52-week high price of Solara Active Pharma Sciences Ltd (SOLARA) is ₹0, while the 52-week low is ₹0. Currently trading at ₹608.55, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Solara Active Pharma Sciences Ltd stock at the current price?
Whether to buy Solara Active Pharma Sciences Ltd stock at ₹608.55 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of 2.08. Today's performance shows a gain of 4.80%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Solara Active Pharma Sciences Ltd and when is the next dividend?
Solara Active Pharma Sciences Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹608.55, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Solara Active Pharma Sciences Ltd?
Solara Active Pharma Sciences Ltd's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: 2.08, ROE: -0.63%, ROCE: 6.01%, Dividend Yield: 0.00%, EPS: ₹-1.68, Book Value: ₹293.2, and Debt-to-Equity: 54.68. The company's market cap stands at ₹2,957.39 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Solara Active Pharma Sciences Ltd stock performing today in the market?
Solara Active Pharma Sciences Ltd stock opened at ₹581.05 and is currently trading at ₹608.55, showing a gain of ₹27.85 (4.80%). The intraday high is ₹619.9 and low is ₹581.05. The trading volume stands at 6,64,223 shares, indicating moderate market participation today.
08What is the P/E ratio of Solara Active Pharma Sciences Ltd and what does it indicate?
Solara Active Pharma Sciences Ltd has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹-1.68, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Solara Active Pharma Sciences Ltd (SOLARA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy